Long-term effects of weight-reducing interventions in hypertensive patients
Long-term effects of weight-reducing interventions in hypertensive patients
复制标题
DOI：
10.1001/archinte.168.6.571
复制
发表时间：
2008-03-24
影响因子：
--
通讯作者：
Siebenhofer, Andrea
中科院分区：
文献类型：
--
作者：
Horvath, Karl;Jeitler, Klaus;Siebenhofer, Andrea
所有主要的抗高血压治疗指南都推荐减肥。我们检索了调查减肥饮食、药物和有创减肥干预对原发性高血压患者患者相关终点和血压（BP）影响的随机对照试验。没有关于对患者相关终点影响的信息。减肥饮食组、奥利司他组或西布曲明组的患者比常规护理组/安慰剂组的患者更有效地减轻了体重。采用减肥饮食治疗的患者血压降低程度更高（收缩压[SBP]：加权平均差[WMD]， -6.3 mm Hg；舒张压[DBP]: WMD， -3.4 mm Hg）或奥利司他（收缩压：WMD， -2.5 mm Hg；舒张压：WMD， -2.0 mm Hg）。西布曲明治疗后收缩压升高（WMD, 3.2 mm Hg）。对于原发性高血压患者，减重饮食或奥利司他治疗可降低体重和血压。虽然西布曲明治疗减轻了体重，但没有降低血压。
Weight loss is recommended in all major guidelines for antihypertensive therapy. We searched for randomized controlled trials investigating the effects of weight-reducing diets, pharmacologic substances, and invasive interventions for weight reduction on patient-relevant end points and blood pressure (BP) in patients with essential hypertension. No information on the effects on patient-relevant end points was available. Patients assigned to weight loss diets, orlistat, or sibutramine reduced their body weight more effectively than did patients in the usual care/placebo groups. Reduction of BP was higher in patients treated with weight loss diets (systolic BP [SBP]: weighted mean difference [WMD], -6.3 mm Hg; diastolic BP [DBP]: WMD, -3.4 mm Hg) or orlistat (SBP: WMD, -2.5 mm Hg; DBP: WMD, -2.0 mm Hg). Systolic BP increased with sibutramine treatment (WMD, 3.2 mm Hg). In patients with essential hypertension, therapy with a weight loss diet or orlistat resulted in reductions in body weight and BP. Although sibutramine treatment reduced body weight, it did not lower BP.